Here we present a case of recurrent glioblastoma in which EGFR gene amplification present in the pre-treatment tumour subsequently disappeared in the tumour that progressed on targeted treatment with the EGFR tyrosine kinase inhibitor dacomitinib. Here, EGFR is linked to neoplasm.